AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
3min chapter
Ep 183: Tom O'Halloran: Is It Time To Be Bullish Again?
Investing With IBD
Arusha Pharmaceuticals' Revenue Drops
Vivgard has the application for this ailment, but many other autoimmune disorders. The sales are exceeding expectations coming out of the gates. We're looking forward to other indications which would be additive to the new drug. And that will determine the future course of this drug. It's a really strong relative strength. So far, you know, the markets agreeing with Tom and his team.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode